ArticleBMC neurology2025
Managing non-motor symptoms of Parkinson disease in China: clinical perspectives.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundParkinson's disease (PD) is a complex neurodegenerative disorder with both motor and non-motor symptoms (NMS), the latter having a profound impact on patients' quality of life (QoL). Increased recognition of NMS underscores the need for comprehensive approaches. The study aimed to evaluate healthcare professionals' awareness and management practices of NMS in PD in China.
methodsA nationwide online survey was conducted among 913 neurologists and psychiatrists from July to October 2023. The questionnaire comprised 65 closed-ended questions addressing basic demographics, awareness, assessment, and treatment strategies for NMS in PD. Chi-square tests were used to analyze differences between the two professional groups.
resultsWhile 95.4% of respondents acknowledged the negative impact of NMS on PD patients' QoL, only 71.0% of neurologists regularly focused on NMS. Approximately half of the NMS were inadequately addressed, with attention to NMS often beginning in the middle to late stages of PD. Significant gaps were identified in awareness and treatment, particularly in managing depression/anxiety, cognitive impairment, and psychotic symptoms. Movement disorder specialists demonstrated higher levels of awareness and management proficiency for NMS.
conclusionsThe study highlights critical gaps in NMS management for PD patients in China, underscoring the need for improved early recognition and appropriate intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.